{'fraction_non_alphanumeric': 0.05585464333781965, 'fraction_numerical': 0.04441453566621804, 'mean_word_length': 4.675572519083969, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pharmacokinetics and urinary excretion of DW116, a new fluoroquinolone antibacterial agent, in humans as a phase I study.

Pharmacokinetics and urinary excretion of the new fluoroquinolone antibacterial agent DW116 [1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1-piperazynyl)-1, 4-dihydro-4-oxoquinolone-3-carboxylic acid, hydrochloride] following oral administration (200, 400, 600 mg) were studied in humans as a phase I study. The plasma concentration of DW116 declined monoexponentially with a half-life range of 16-22 hr. The area under the curve (AUC) and Cmax increased proportionally as the dose increased. The T1/2 and mean residence time (MRT) (28.3-30.9 hr) were independent of dose. The Tmax appeared within 3 hr (0.9-2.7 hr) after drug administration. The Ka ranged from 1.3 to 4.1 (hr-1). The plasma half-life was much longer, and Cmax was higher by about two- to three-fold than conventional fluoroquinolones. Urinary recovery of DW116 was 29.6-61.6% of the dose. The maximum excretion rate appeared within 4 hr and decreased continuously after drug administration. A urinary metabolite was not detected in the urine extract obtained before and after hydrolysis by beta-glucuronidase (from Escherichia coli); this was different from other fluoroquinolone antibacterial agents. Poor metabolism in the kidney may contribute to the good oral bioavailability, but due to the low recovery (< 60%) in urine, it is possible that DW116 is metabolized in the liver or other organs.